Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial.

PA, Frith; PJ, Thompson; R, Ratnavadivel; CL, Chang; P, Bremner; P, Day; C, Frenzel; N, Kurstjens

doi:10.1136/thoraxjnl-2014-206670

Public

Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial.

Shared by NobleBlocks on Apr 3, 2015 • 12:00 AM UTC

Authors:

Frith PA

Thompson PJ

Ratnavadivel R

Abstract

Background The optimal use of various therapeutic combinations for moderate/severe chronic obstructive pulmonary disease (COPD) is unclear. The GLISTEN trial compared the efficacy of two long-acting anti-muscarinic antagonists (LAMA), when combined with an inhaled corticosteroid (ICS) and a long-act...

Subject

Copd Pharmacology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!